KOSPIBiotech & Pharma003850

Boryung

₩8,660▼ 0.35%2026-11-18 close
Market Cap
₩742.9B
Turnover
₩400M
Volume
50K
Shares out.
85.8M
PER
9.9×
PBR
0.8×
EPS
₩878
Dividend Yield
1.84%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩160 per share · Prices as of the 2026-11-18 close

01

Report overview

Boryung: Oncology Sales Lift Top Line, Margins Lag

Boryung's cumulative operating profit for the first three quarters of 2026 surpassed its full-year 2025 operating profit, driven by the Taxotere acquisition and growth in its Canav hypertension franchise, but in the third quarter alone operating profit fell and the company swung to a loss attributable to controlling shareholders as amortization costs rose.

  1. 1

    On the 2025 annual report, sales were KRW 1.02 trillion, flat from 2024, while operating profit fell 7.7% to KRW 65.1 billion.

  2. 2

    Third-quarter 2026 sales rose 12.4% from the prior quarter to KRW 314.4 billion, yet operating profit was KRW 25.5 billion and the company posted a net loss attributable to controlling shareholders of KRW 13.2 billion.

  3. 3

    Cumulative operating profit of KRW 69.4 billion for the first three quarters (preliminary, disclosed October 22, 2026) exceeded the full-year 2025 operating profit of KRW 65.1 billion.

  4. 4

    Taxotere generated KRW 27.7 billion in third-quarter sales, and cumulative oncology sales grew 24.1%, leading top-line growth.

  5. 5

    Operating cash flow rose from KRW 27.8 billion in 2022 to KRW 133.2 billion in 2025, and the debt-to-equity ratio at the end of 2025 was 64.1%.

02

Business structure

Boryung, founded in 1963 and listed on the KOSPI in 1988, runs ethical pharmaceuticals (ETC), oncology, over-the-counter drugs and contract business.

In the third quarter of 2026, ETC sales reached KRW 283.6 billion, up 18.2% year on year, while OTC sales fell 6.2% to KRW 19.4 billion and contract business fell 38.3% to KRW 11.7 billion.

Cumulative oncology sales for the first three quarters of 2026 rose 24.1% to KRW 221.4 billion, and the gross margin in that segment improved 5.2 percentage points to 41.4%.

Taxotere, a cytotoxic anticancer drug acquired from Sanofi in 2025, began recording sales in June, and its third-quarter sales of KRW 27.7 billion (KRW 6.4 billion domestic, KRW 21.3 billion overseas) equaled 30.5% of third-quarter oncology sales of KRW 90.9 billion.

The hypertension franchise Canav recorded third-quarter sales of KRW 36.0 billion; excluding a KRW 8.7 billion provision related to a drug price cut lawsuit, sales were KRW 44.7 billion, up 5.2% year on year.

Prescriptions for the franchise rose 7.1%, ahead of a 4.2% growth rate in the hypertension market, and the company reported a 56% share of the three-drug combination market in September. The lipid-lowering drug L-family grew 37.1% to KRW 7.1 billion, and the kidney disease product group rose 15.2% to KRW 19.5 billion.

The contract development and manufacturing (CDMO) business began in earnest with the first shipment of Alimta production volume to Taiwan's Lotus in May 2026, following a December 2024 agreement. Boryung Holdings and nine related parties held 64.78% as of September 1, 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩280B₩29.4B10.5%
2025Q4₩245.3B-₩600M−0.3%
2026Q1₩255.4B₩20.2B7.9%
2026Q2₩279.6B₩23.8B8.5%
2026Q3₩314.4B₩25.5B8.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩760.5B₩56.6B₩41.9B7.4%8.1%72.8%
2023₩859.6B₩68.3B₩40.2B7.9%7.3%66.7%
2024₩1T₩70.5B₩69.6B6.9%8.9%48.4%
2025₩1T₩65.1B₩64.3B6.4%7.6%64.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On the annual disclosed figures, sales rose from KRW 760.5 billion in 2022 to KRW 859.6 billion in 2023 (up 13.0%) and KRW 1.02 trillion in 2024 (up 18.3%), then held at KRW 1.02 trillion in 2025.

Operating profit went from KRW 56.6 billion in 2022 to KRW 68.3 billion in 2023 (up 20.6%) and KRW 70.5 billion in 2024 (up 3.2%), then fell 7.7% to KRW 65.1 billion in 2025. The operating margin was 7.4% in 2022, 7.9% in 2023, 6.9% in 2024 and 6.4% in 2025, so it peaked in 2023 and has declined since.

Net income attributable to controlling shareholders was KRW 69.6 billion in 2024, up 73.2%, the largest of the 2022 to 2025 period, dropped to KRW 40.2 billion in 2023, and reached KRW 64.3 billion in 2025, down 7.7%.

The gap between sales growth and margin compression was most visible in 2024, and in 2025, the year the Taxotere business was acquired, the debt-to-equity ratio rose from 48.4% to 64.1%.

Operating cash flow increased each year, from KRW 27.8 billion in 2022 to KRW 42.2 billion in 2023, KRW 80.6 billion in 2024 and KRW 133.2 billion in 2025.

Quarterly, fourth-quarter 2025 sales fell 12.4% from the prior quarter to KRW 245.3 billion and the company recorded an operating loss of KRW 649 million, a swing from profit.

First-quarter 2026 operating profit of KRW 20.2 billion turned positive, followed by KRW 23.8 billion in the second quarter (up 18.1% quarter on quarter) and KRW 25.5 billion in the third quarter (up 7.1%).

Third-quarter operating profit was still 13.4% lower than a year earlier, and press coverage attributed the decline partly to amortization of KRW 12.8 billion related to the Taxotere acquisition, up 122.0% year on year, along with higher labor and fee costs.

Financial income and expenses swung to a KRW 44.6 billion loss in the same quarter, mainly from foreign currency translation losses after the won weakened, which produced a net loss attributable to controlling shareholders of KRW 13.2 billion.

Net income attributable to controlling shareholders for the last four quarters (fourth quarter 2025 to third quarter 2026) totaled KRW 73.4 billion.

05

Industry analysis

Boryung is built around ethical drugs, centered on chronic cardiometabolic treatments and cytotoxic anticancer drugs. The hypertension market grew 4.2% in the third quarter of 2026, while Boryung's Canav franchise prescriptions rose 7.1%, ahead of the market.

Drug pricing is a variable for profitability in this market, and the third-quarter Canav sales figure includes a KRW 8.7 billion provision tied to a drug price cut lawsuit, which makes quarter-to-quarter sales comparisons sensitive to provisioning.

Cytotoxic anticancer capacity is scarce, and the company has described frequent supply shortages and raw material supply instability in this segment.

Boryung's Yesan plant holds domestic GMP and EU-GMP certification for its cytotoxic anticancer facility, and the company said it is preparing for cGMP certification required by the US FDA.

On biologics, the company said the Korean market for major biologic drugs losing patent protection by 2030 is about KRW 2 trillion, and it stated that it would secure biosimilar pipelines.

This positions Boryung differently from Samsung Biologics and Celltrion, which focus more directly on biologic manufacturing and biosimilar development.

Boryung is widening its base from a domestic prescription-driven model toward global oncology and CDMO, and the results of that shift will show up in future reported earnings.

06

Outlook

In its CEO letter, the company said it expects cash flow to continue in 2026 and described using those funds for investment in essential drug production infrastructure, including penicillin and cytotoxic anticancer capacity, and for the global Taxotere business.

The company expects Taxotere to generate more than about KRW 90 billion in sales from 2027. Consolidated sales for the first half of 2026 were KRW 535.0 billion and operating profit was KRW 44.0 billion, which the company described as record half-year figures in its disclosure on August 6, 2026.

Canav-Jet, launched in May, completed KRW 3.7 billion in initial shipments during the first half. For the fourth quarter, the company said it plans to lift profitability through expanded sales of chronic cardiometabolic drugs including Canav-Jet and by stabilizing its global anticancer business.

In CDMO, the Yesan campus has shipped Alimta volumes and shown its production capacity, and some commentary expects mid-term sales growth and profitability gains. On regulatory certification, securing FDA cGMP certification is viewed as an important task.

The Canav drug price cut lawsuit is being reflected in results through provisions, so quarterly sales patterns could change depending on the outcome. The direction of Boryung's earnings will depend on how far the operating margin recovers from 8.1% in the third quarter of 2026.

07

Valuation

PER
9.9×
PBR
0.8×
ROE
8.7%
EPS
₩878
BPS
₩10,368
Dividend per share
₩160

Valuation can be viewed through two lenses, assets and earnings. On an asset basis, the share price sits at a low level relative to total equity, with the price-to-book ratio below 1x.

Of the KRW 845.5 billion in total equity at the end of 2025, the portion attributable to controlling shareholders is the same amount, so there is no non-controlling interest gap in that comparison.

On an earnings basis, net income attributable to controlling shareholders fell from KRW 69.6 billion in 2024 to KRW 64.3 billion in 2025, and the last four quarters total KRW 73.4 billion.

Those four quarters include KRW 21.1 billion in fourth-quarter 2025, KRW 41.4 billion in first-quarter 2026, KRW 24.1 billion in the second quarter, and a net loss of KRW 13.2 billion in the third quarter, so quarterly swings are large.

Because quarterly earnings vary this much, the price relative to earnings reads differently depending on the period chosen. The company has stated in its CEO letter that it intends to continue shareholder returns.

The result is a low share price relative to book value alongside uneven quarterly earnings, and how the situation is read depends on which measure is given more weight.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Global oncology sales ramp up

Taxotere, a cytotoxic anticancer drug acquired from Sanofi in 2025, began booking sales in June 2026. Of third-quarter Taxotere sales of KRW 27.7 billion, KRW 21.3 billion came from overseas, lifting the global share of oncology sales from 10.9% in the second quarter to 24.2% in the third.

The company said it holds worldwide marketing, approval, production and trademark rights, including Korea. The company expects the product to generate more than about KRW 90 billion in sales from 2027, according to its CEO letter.

Chronic disease prescriptions growing

Canav franchise prescriptions in the third quarter of 2026 rose 7.1% year on year, ahead of 4.2% growth in the hypertension market. Canav-Jet passed KRW 1 billion in monthly prescription value within four months of launch.

L-family sales rose 37.1% to KRW 7.1 billion, and the kidney disease product group grew 15.2% to KRW 19.5 billion. Prescription data is compiled on a different basis from the company's reported sales.

Rising operating cash flow

Operating cash flow rose from KRW 27.8 billion in 2022 to KRW 133.2 billion in 2025. The company disclosed on August 6, 2026 that first-half consolidated sales reached KRW 535.0 billion and operating profit KRW 44.0 billion, both record half-year figures. The company said it is directing this cash to production infrastructure and the global Taxotere business.

09

Bear factors

Third-quarter profitability slowed

Third-quarter 2026 operating profit was KRW 25.5 billion, down 13.4% year on year, and the operating margin fell 2.4 percentage points to 8.1%. Amortization tied to the Taxotere acquisition reached KRW 12.8 billion, up 122.0%, and operating expenses rose about 24% to KRW 91.6 billion.

Sales rose 12.3% over the same period, but cost growth outpaced it. The company cited higher selling and administrative expenses for the new product launch and amortization as the main factors.

Volatility in financial income and expenses

Third-quarter 2026 financial income and expenses swung to a KRW 44.6 billion loss, from a KRW 15.4 billion gain a year earlier. The company attributed the swing mainly to foreign currency translation losses as the won weakened, which produced a net loss attributable to controlling shareholders of KRW 13.2 billion.

Consolidated cash and cash equivalents fell 76.1% from KRW 227.6 billion at the end of 2025 to KRW 54.3 billion at the end of the third quarter, while short-term financial and investment assets rose to KRW 79.0 billion.

Canav price-cut lawsuit and sales swings

Canav franchise sales in the third quarter of 2026 were KRW 36.0 billion, down 15.3% year on year. Excluding the KRW 8.7 billion provision linked to the drug price cut lawsuit, sales were KRW 44.7 billion, up 5.2%.

The gap between reported and adjusted figures is wide, so quarterly trends in the flagship franchise are harder to read while the litigation continues.

10

Risk factors

Drug pricing and litigation

The Canav franchise is recording provisions linked to a drug price cut lawsuit, so quarterly sales of the flagship product can move with policy and court outcomes. Third-quarter 2026 Canav sales were KRW 36.0 billion after the provision and KRW 44.7 billion before it.

Even with prescription growth, lower drug prices would pressure both sales and profit. This risk is unlikely to clear before the litigation is resolved.

Currency and financial income

Third-quarter 2026 financial income and expenses recorded a KRW 44.6 billion loss, driven by foreign currency translation losses. As global Taxotere sales and overseas investment assets grow, the company's foreign currency exposure is also increasing.

If the exchange rate moves against it, non-operating items unrelated to core operations can decide net income. The swing into a quarterly net loss was driven by this item, so sensitivity is high.

Execution of acquired business

Amortization tied to the Taxotere acquisition reached KRW 12.8 billion in the third quarter of 2026, as a full three months were recorded for the first time. The company is preparing for FDA cGMP certification, so the expansion of overseas CDMO work may depend on that timeline.

If Taxotere sales do not reach the roughly KRW 90 billion projected for 2027, recovery of acquisition costs would slow. If operating margins do not recover, amortization could weigh on profit over the long term.

11

What to watch next

  1. Around late January 2027 (expected)

    The timing of the preliminary fourth-quarter and full-year 2026 results. This estimate is based on the precedent that the third-quarter 2026 preliminary results were disclosed on October 22, 2026. Watch the fourth-quarter operating margin, the size of the Canav litigation provision and the trend in Taxotere amortization.

  2. By March 31, 2027

    The filing deadline for the 2026 annual report, which will be the next regular report. The confirmed annual operating margin, debt-to-equity ratio and operating cash flow are the check points. It will also show whether the debt-to-equity ratio, which rose to 64.1% in 2025, shifts by year-end 2026.

  3. By May 15, 2027

    The filing deadline for the first-quarter 2027 report. Watch whether Taxotere amortization and global oncology sales settle into a steady quarterly pattern, and whether the operating margin recovers above the 8.1% recorded in the third quarter of 2026.

  4. During 2027

    The timing of the roughly KRW 90 billion in Taxotere sales the company projected and the outcome of preparations for US FDA cGMP certification. Confirmation of both items would show whether the overseas oncology and CDMO expansion is on track.

12

Overall view

Boryung's revenue has stayed in the KRW 1 trillion range since 2024, and cumulative operating profit for the first three quarters of 2026 of KRW 69.4 billion (preliminary, disclosed October 22, 2026) surpassed the full-year 2025 operating profit.

Growth has come from the oncology segment, including Taxotere, and from rising Canav franchise prescriptions, with cumulative oncology sales up 24.1%. Profitability is weaker. Third-quarter 2026 operating profit fell 13.4% year on year and the operating margin dropped 2.4 percentage points to 8.1%.

The company attributed the quarterly loss to amortization, higher costs and financial losses from currency movements. Operating cash flow rose from KRW 27.8 billion in 2022 to KRW 133.2 billion in 2025, supporting investment funds.

Strengths include the ramp of global oncology sales, prescription growth for new products such as Canav-Jet, and higher cash generation, while weaknesses include amortization burden, the Canav litigation provision and currency-driven swings in financial results.

The next checkpoints are whether the operating margin recovers in the 2026 annual report (due by March 31, 2027) and the first-quarter 2027 report (due by May 15, 2027), and whether Taxotere sales reach the level the company has projected.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. m.news.nate.com
  2. huffingtonpost.kr
  3. m.news.nate.com
  4. m.news.nate.com
  5. news.nate.com
  6. boryung.co.kr
  7. comp.wisereport.co.kr
  8. modoobid.co.kr
  9. kormedi.com
  10. biz.newdaily.co.kr
  11. kpanews.co.kr
  12. newsprime.co.kr
  13. m.news.nate.com
  14. economytalk.kr
  15. dealsite.co.kr
  16. dailian.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis